Parcel and logistics giant UPS Inc. is continuing to grow its footprint in the lucrative niche of cold chain logistics, announcing today that it has invested $48 million in 27 temperature-controlled freight cross-dock facilities around the globe.
UPS said the facilities are optimized for speed and short-term storage between air and ground movements – all while maintaining specific temperature requirements.
The Atlanta-based company said it has made the move as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen. More specifically, the rapidly growing biologics pipeline is increasing complexity across cold-chain logistics.
“Biologics and personalized treatments are driving better, more targeted care for patients,” said John Bolla, President of UPS Healthcare. “These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.”
Meeting that demand requires cold-chain expertise to maintain product quality and safety from manufacturing to patient, UPS said. “We have aligned our investments with our Healthcare customers’ specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS.
